title: [Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma].
abstract: Intra-arterial hepatic chemotherapy (LAHC) results in significantly higher response rate than the best systemic treatment of liver metastases from colorectal cancer, but no survival advantage has to date shown because of extra-hepatic progression. From June 1991 to December 1994, twenty patients with hepatic metastases from colorectal cancer were enrolled. All patients underwent laparotomy for the placement of an intra-arterial catheter into the gastroduodenal artery connected with a subcutaneous port. All patients underwent cholecystectomy and biopsy of liver lesion to confirm metastatic disease. Locoregional schedule was: 5-fluorouracil (5FU) 500 mg/sqm, epirubicin (EPI) 13 mg/sqm, mitomycin-C (MMC) 7 mg/sqm, in bolus every 3 weeks. Systemic therapy consisted of leucovorin 500 mg/sqm, over 2 hours and 5FU 600 mg/sqm in bolus every week. Treatment was planned over a six month period. The complete response (CR) plus partial response (PR) rate was 50% of the entire group. The median survival was 18 months and 1- and 2- and 3-year survival rates were 71%, 38% and 20% respectively. Prior to chemotherapy, LDH value and % of liver involvement were the only significant prognostic parameters. Toxicity was absent or mild and no patient stopped treatment because of side effects. Combined systemic and IAHC is an effective treatment for liver metastases from colorectal cancer, with a mild or moderate toxicity. However, more trials are needed, to improve the control of the extrahepatic disease.
authors.affiliation: Divisione di Oncologia, Azienda Ospedaliera C. Poma-Mantova.
authors.forename: M
authors.initials: M
authors.lastname: Cantore
authors.forename: E
authors.initials: E
authors.lastname: Aitini
authors.forename: C
authors.initials: C
authors.lastname: Rabbi
authors.forename: G
authors.initials: G
authors.lastname: Cavazzini
authors.forename: M
authors.initials: M
authors.lastname: Bertani
authors.forename: C
authors.initials: C
authors.lastname: Pulica
authors.forename: S
authors.initials: S
authors.lastname: Campo
authors.forename: F
authors.initials: F
authors.lastname: Pari
authors.forename: A
authors.initials: A
authors.lastname: Mambrini
authors.forename: A
authors.initials: A
authors.lastname: Bezzi
authors.forename: D
authors.initials: D
authors.lastname: Zamagni
authors.forename: M
authors.initials: M
authors.lastname: Amadori
authors.forename: F
authors.initials: F
authors.lastname: Smerieri
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000931:Antidotes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D015251:Epirubicin; D016685:Mitomycin; D002955:Leucovorin; D005472:Fluorouracil